Latest Pneumococcal polysaccharide vaccine Stories

The pneumococcal vaccine for infants and children introduced in 2000 caused a precipitous drop in infections until 2005, when serious illnesses began to rise again, especially infections caused by a strain of the pneumococcal bacteria called 19A, said researchers from Baylor College of Medicine and Texas Children's Hospital in a report in the current issue of the journal Pediatrics."Of the serotypes (or variants) of Streptococcus pneumoniae (the bacteria that cause pneumococcal disease)...

Rituximab treatment reduced patient response to pneumonia vaccineResearchers from Johns Hopkins University determined that immune responses to the tetanus vaccine were not changed when rituximab in combination with methotrexate (MTX) was compared with MTX alone in patients with rheumatoid arthritis (RA). Responses to a pneumococcal vaccination (Pneumovax® pneumonia vaccine), however, were reduced in RA patients with rituximab. Complete findings of this study are published in the January...

On Wednesday U.S. health officials expressed concern over a trend towards increased incidence of bacterial infections in young adults who have contracted the swine flu.Though serious bacterial infections are not uncommon for patients suffering from the flu, the particularly high rate at which it is affecting young people"”typically the most resilient group against such infections"”has given health experts a bit of an alarm.  Dr. Anne Schuchat of the U.S. Centers for Disease Control and...

SCOTTSDALE, Ariz., Oct. 27 /PRNewswire/ -- Acknowledging the critical role of Centers for Disease Control and Prevention (CDC) guidelines in ensuring the safety and efficacy of H1N1 vaccinations, Carefx Corporation, a leading provider of interoperable workflow solutions to advance the quality and safety of patient care, today announced that Boston Medical Center (BMC) has deployed the Fusionfx Immunization Management portal designed to enter and track H1N1 vaccination administration history...

Many people who have died of H1N1 influenza in the United States had other bacterial infections that likely contributed to their deaths, health officials say. A report published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report says those who died of H1N1 influenza had co-infections with a common bacteria such as Streptococcus pneumoniae or pneumococcus. The CDC report included an analysis of specimens taken from 77 fatal cases of H1N1. Bacterial...

COLLEGEVILLE, Pa., Aug. 11 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced it received notice that the action date for the U.S. Food and Drug Administration's (FDA) review of the Biologics License Application (BLA) for Prevnar 13(TM), (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) has been extended from September 30, 2009, to December 30, 2009. In response to an FDA request, Wyeth submitted additional analytical method...

Infants who received two or three primary doses of the 7-valent pneumococcal conjugate vaccine (PCV-7) both had a decreased rate of carrying pneumococcal microorganisms that can cause pneumonia and other infections, compared to infants who were not vaccinated, according to a study in the July 8 issue of JAMA.Crowded infant vaccine schedules and less favorable cost-effectiveness calculations have prompted exploration of reduced-dose vaccine schedules other than the currently recommended...

-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- COLLEGEVILLE, Pa., May 7 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) granted priority review to the company's Biologic License Application (BLA) for Prevnar 13*, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein), which was submitted on March 31....

Infants who receive the pneumococcal conjugate vaccine (PCV) following the combination vaccine for diphtheria, polio, tetanus, pertussis and Haemophilus influenzae type b (DPTaP-Hib vaccine) appear to experience less pain than those who are immunized in the opposite order, according to a report in the May issue of Archives of Pediatrics & Adolescent Medicine, a theme issue on vaccines.Injections are the most painful common medical procedure conducted in childhood, according to background...

- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease - COLLEGEVILLE, Pa., March 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Prevnar 13(TM), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein). Last year, the FDA granted Prevnar 13 Fast Track...